Cultural advice

The Australian National University acknowledges, celebrates and pays our respects to the Ngunnawal and Ngambri people of the Canberra region and to all First Nations Australians on whose traditional lands we meet and work, and whose cultures are among the oldest continuing cultures in human history.

Aboriginal and Torres Strait Islander peoples are advised that ANU Library collections may include images, names, voices, and other representations of deceased persons.

Material in the collection may contain terms, language or views that reflect the period in which the item was created and may be considered inappropriate today.

Optimal Adjuvant Endocrine Therapy for Early Breast Cancer

Date

Authors

Stuart-Harris, Robin

Davis, Alison

Publisher

Future Science Group

Abstract

Adjuvant endocrine therapy substantially reduces tumor recurrence and mortality in pre- and post-menopausal women with hormone receptor-positive early breast cancer but is ineffective in women with hormone receptor-negative tumors. Tamoxifen has been the

Keywords

Keywords: aminoglutethimide; anastrozole; antineoplastic agent; aromatase inhibitor; cyclophosphamide; doxorubicin; exemestane; fluorouracil; formestane; gonadorelin agonist; goserelin; letrozole; leuprorelin; methotrexate; paclitaxel; placebo; tamoxifen; tamoxifen Adjuvant endocrine therapy; Aromatase inhibitors; Breast cancer mortality; Disease-free survival; Estrogen receptor; LHRH agonists; Luteinising hormone-releasing hormone agonists; Ovarian ablation; Ovarian function suppression; Overall survival; Tamoxifen

URI

http://hdl.handle.net/1885/52329

Collections

ANU Research Publications

Source

Women's Health

Type

Journal article

DOI

10.2217/whe.10.25

Restricted until

2037-12-31

Downloads

File

Description

01_Stuart-Harris_Optimal_Adjuvant_Endocrine_2010.pdf (540.27 KB)